SCHEMBL4071018

SCHEMBL4071018

O=C(c1cn(-c2nccc3ccccc23)c2ncccc12)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.52
CNR2 P34972 5/20 0.43
HTT P42858 1/20 0.41
COMT P21964 1/20 0.40
RORC P51449 5/20 0.38
KDM4E B2RXH2 1/20 0.38
CNR1 P21554 2/20 0.38
HCAR2 Q8TDS4 1/20 0.38
IDO1 P14902 1/20 0.38
PDE4A P27815 1/20 0.37
KCNH2 Q12809 1/20 0.37
DPP4 P27487 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
CYP2C9 P11712 2/20 0.36
HRH4 Q9H3N8 1/20 0.36
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065134 0.85 HCAR2 (0.48) CNR2COMTRORCKDM4ECNR1
Hydrochloric Acid SCHEMBL4061832 0.83 COMT (0.41) CNR2COMTRORCKDM4ECNR1
SCHEMBL7173601 0.80 PDE4A (0.50) COMTRORCKDM4EHCAR2PDE4A
SCHEMBL4058546 0.80 ATM (0.53) ATMHTTRORCKDM4EIDO1
SCHEMBL4061010 0.79 ATM (0.50) ATMCNR2HTTRORCKDM4E
SCHEMBL4062806 0.78 PDE4A (0.40) CNR2COMTKDM4ECNR1HCAR2
SCHEMBL21979497 0.74 HTT (0.60) ATMHTTKDM4EIDO1
SCHEMBL31404665 0.74 HTT (0.60) ATMHTTKDM4EIDO1
SCHEMBL7185144 0.73 TDP1 (0.51) HTTKDM4EPDE4AKCNH2
SCHEMBL7173592 0.73 KCNH2 (0.48) CNR2KDM4ECNR1PDE4AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1641791-B1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-29 EP disclosed
US-7230007-B2 Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-06-12 US disclosed
EP-1641791-A1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM Sanofi-Aventis Deutschland GmbH (DE) 2006-04-05 EP disclosed
US-20050014758-A1 Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-01-20 US disclosed
WO-2004111048-A1 3-(GUANIDINOCARBONYL)HETEROCYCLE DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS, THEIR USE AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014758-A1 Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom TNNI3, TNNT2, TNNC1 ATM 2939/4885CNR2 1309/4885HTT 4335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.